Search

News Metamizole in Pain Management for Patients with Subarachnoid Hemorrhage

A study by Czech authors from the University Hospital St. Anna in Brno, recently published in the British Journal of Neurosurgery, evaluated analgesic treatment in patients with subarachnoid hemorrhage. The use of metamizole as the primary analgesic was associated with a significantly lower risk of adverse clinical outcomes at 2 weeks and 6 months compared to other non-opioid and opioid analgesics.

Source: Analgesia 10. 5. 2023

News Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer

The KATHERINE clinical trial demonstrated that adjuvant therapy with trastuzumab emtansine compared to trastuzumab significantly improves invasive disease-free survival in patients with HER2-positive early breast cancer and residual invasive disease after prior treatment. A post hoc analysis of this study was published in the journal Cancer, focusing on patient-reported outcomes related to quality of life during and after treatment.

Source: Breast Carcinoma 28. 5. 2020

Články časopisu Advances in the therapy of small cell lung cancer

Author of the article: D. Vrána Source: Klinická onkologie | Supplementum 1/2021 27. 5. 2021

News Overlap of SGLT2 Inhibitors from Diabetology to Cardiology

As recent research shows, one of the modern groups of antidiabetic drugs -⁠ SGLT2 inhibitors, also known as gliflozins -⁠ brings benefits not only in diabetology but also in cardiology and nephrology. It has been confirmed that representatives of this class of drugs prolong patients' lives, reduce the incidence of major cardiovascular (CV) events and the risk of heart failure (HF), and improve renal function. A recently published study additionally indicates that the CV benefit of empagliflozin is independent of the number of compensated CV risk factors and manifests within the first 3 months of treatment.

Source: Diabetes 29. 10. 2021

News Clinical Significance of Smaller Gaps Between Strengths of Levothyroxine Preparations in the Treatment of Hypothyroidism

Many levothyroxine preparations have relatively large intervals between doses (25 µg, 50 µg, and 75 µg), creating obstacles for some patients to achieve an optimal maintenance dose. The availability of tablets that allow for dosing in between these values facilitates precise and effective titration of levothyroxine doses, especially at the lower end of the spectrum.

Source: Thyroid Disorders 23. 2. 2024

News How Does the Long-Term Effect of Beta Blocker Use Affect Clinical Outcomes in Patients After Myocardial Infarction?

In patients after myocardial infarction (MI), beta blockers (BB) still hold an important place in secondary prevention according to recommended procedures. However, the question could be their long-term effect on clinical outcomes, as different results can be found in the literature –⁠ this fact led the authors of the work cited below to perform a systematic review and meta-analysis of studies dedicated to this issue.

Source: Cardiovascular Continuum 25. 10. 2023

News Progress on Lorlatinib –⁠ What's Next?

Lorlatinib is currently mainly used in the 2nd and later lines of treatment for non-small cell lung cancer (NSCLC) with ALK gene rearrangement. Clinical research is now focusing on the question of how to proceed with patients who experience disease progression during lorlatinib treatment in later lines of therapy. It seems that one of the options might actually be to do nothing –⁠ to continue with lorlatinib.

Source: Genetic Profile and Treatment of NSCLC 17. 5. 2022

News Reversal of Dabigatran Effects with Idarucizumab in Patients Requiring Urgent Procedures: Subanalysis of the RE-VERSE AD Study

The effect of idarucizumab as a reversal agent in patients treated with dabigatran in situations requiring urgent surgery or other invasive procedures was evaluated in a subanalysis from the RE-VERSE AD study published in 2021.

Source: Anticoagulant Treatment 18. 11. 2021

News Therapy with Cyclosporine in the Context of the Coronavirus Pandemic

The rapid spread of the SARS-CoV-2 virus and the associated COVID-19 disease pandemic raises concerns about possible risks associated with immunosuppressive treatment of autoimmune diseases. Specifically, does the use of cyclosporine increase the risk of infection, or does it act protectively?

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 14. 4. 2021

Články časopisu Gynecologic robotic surgery and our initial experience

Author of the article: R. Pilka, P. Dzvinčuk Source: Česká gynekologie | 6/2010 20. 12. 2010

News Idarucizumab reverses the anticoagulant effect of dabigatran even in patients with impaired renal function –⁠ clinical practice commentary

Along with the results of a subanalysis of the RE-VERSE AD study, which demonstrated the efficacy of idarucizumab in reversing the anticoagulant effect of dabigatran regardless of the level of renal function impairment, the October issue of the Journal of the American College of Cardiology also featured an editorial commentary by Californian cardiologists on its conclusions.

Source: Anticoagulant Treatment 10. 2. 2020

News Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage

The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the fixed triple combination, which in addition to these two substances also includes glycopyrronium bromide (LAMA), Enerzair® for maintenance inhalation treatment of bronchial asthma, approved in the EU last year, have established health insurance coverage in the Czech Republic from May 1, 2021. We bring a summary of the conditions for reimbursement.

Source: Asthma under control 2. 9. 2021

News Dravet Syndrome –⁠ Get to Know It

Dravet syndrome is a severe myoclonic epilepsy occurring in early childhood. It is classified as a rare progressive epileptic encephalopathy, characterized by generalized or lateralized clonic seizures often prolonged and linked to febrile infections. Other forms of seizures later appear, leading to deterioration in psychomotor development and the onset of mental retardation. Early diagnosis and treatment are desirable.

Source: Rare Diseases in Neurology 2. 5. 2023

News Dyslipidemia in the General Practitioner's Office –⁠ Featuring LDL Cholesterol

Monitoring LDL cholesterol (LDL-c) levels is crucial in diagnosing hypercholesterolemia as it is directly linked to increased cardiovascular risk. What other tests should be performed upon detecting hypercholesterolemia and which medications can effectively help reduce LDL-c levels?

Source: Hypercholesterolemia 9. 12. 2021

News Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor antagonist −⁠ NK1RA) with palonosetron (a 5-HT3 receptor antagonist) offer prevention of chemotherapy-induced nausea and vomiting (CINV) for up to 5 days after its administration. Although the i.v. form of netupitant (fosnetupitant) + palonosetron (NEPA) did not lead to injection site reactions or anaphylactic reactions in a Phase III study, hypersensitivity and anaphylactic reactions have been described with other i.v. administered NK1RAs. Thus, the aim of the study recently published in the journal The Oncologist was to evaluate the safety and efficacy of i.v. NEPA in women with breast cancer treated with anthracycline and cyclophosphamide-containing chemotherapy.

Source: Antiemetic Therapy 20. 1. 2020